Aurora kinase A (AURKA) phosphorylates NSD2 at S56, enhancing its methyltransferase activity and promoting chemotherapy resistance in t(4;14) MM patients (Jiang et al., 2022b). Here, NSD2 is linked to Miyoshi myopathy.